histone H3T6 kinase activity GO:0035403

GO:0035403, histone H3T6 kinase activity, is a Gene Ontology molecular_function term that describes the catalytic addition of a phosphate group to threonine 6 of histone H3 using ATP. This post-translational modification occurs on the histone H3 tail, a region dense with regulatory marks that influence chromatin structure and gene expression. Because histone H3 threonine 6 sits immediately adjacent to lysine 4, phosphorylation at T6 can directly influence the methylation status of H3K4, a hallmark of active transcription. The term therefore captures a specific enzymatic activity that bridges intracellular kinase signaling and epigenetic regulation. The prototype enzyme for this activity is protein kinase C beta (PKC-beta), which was shown to phosphorylate histone H3 at threonine 6 and thereby control demethylation at histone H3K4. This finding established H3T6 phosphorylation as a chromatin-modifying event with functional consequences for gene activation and cell fate. Subsequent work has connected H3T6 phosphorylation to developmental processes such as myoblast differentiation, where muscle-specific pyruvate kinase isoforms regulate SWI/SNF proteins and histone H3 phosphorylation. In cancer, the EWSR1-FLI1 oncogene induces PKC-beta, and targeting this kinase abolishes Ewing sarcoma growth, highlighting the disease relevance of this activity. For researchers, GO:0035403 provides a precise annotation target for studying how kinase signaling rewires chromatin. Understanding which enzymes carry this activity, which substrates they modify, and how the mark is read and erased is essential for dissecting transcriptional control in development and disease. This article summarizes the definition, mechanism, key genes, disease links, and experimental strategies for investigating histone H3T6 kinase activity.

Histone H3T6 kinase activity (GO:0035403) is the catalysis of the reaction in which histone H3 threonine at position 6 is phosphorylated using ATP, yielding histone H3 phosphothreonine at position 6 and ADP. In other words, it is the enzymatic activity that adds a phosphate group specifically to threonine 6 of histone H3. This activity is a molecular_function annotation and is distinct from other histone kinase activities that target different residues or different histones.

Histone H3T6 kinase activity is important because it places a specific phosphorylation mark on the histone H3 tail that can influence nearby chromatin modifications and gene expression programs. The best-studied example, PKC-beta-mediated H3T6 phosphorylation, controls demethylation at H3K4 and thereby affects transcriptional activation. This activity links extracellular and intracellular signaling pathways to epigenetic states, making it a focal point for understanding how cells convert signals into stable changes in gene expression. In disease, aberrant H3T6 kinase activity has been connected to cancer, including Ewing sarcoma, where PKC-beta is induced by an oncogenic fusion protein and is required for tumor growth. In development, histone H3 phosphorylation is dynamically regulated during myoblast differentiation, implicating this activity in tissue formation.

The following genes and proteins are directly or indirectly implicated in histone H3T6 kinase activity, its regulation, or its biological consequences based on the cited literature.

Histone H3T6 kinase activity is regulated at multiple levels. The prototype enzyme PKC-beta is activated by upstream signaling pathways, and its induction by the EWSR1-FLI1 oncogene in Ewing sarcoma leads to increased H3T6 phosphorylation. In muscle differentiation, pyruvate kinase isoforms PKM1 and PKM2 regulate SWI/SNF proteins and histone H3 phosphorylation, indicating that metabolic state can influence this activity. Because H3T6 phosphorylation controls H3K4 demethylation, the balance between kinase and phosphatase activities determines the persistence of the mark and its impact on transcription.

In Ewing sarcoma, the EWSR1-FLI1 oncogene induces protein kinase C beta, which carries histone H3T6 kinase activity. Targeting PKC-beta abolishes Ewing sarcoma growth, demonstrating that this activity is required for tumor maintenance. This makes H3T6 phosphorylation a potential biomarker and therapeutic target in Ewing sarcoma.

Because H3T6 phosphorylation by PKC-beta controls H3K4 demethylation, it can influence gene expression programs that drive proliferation and survival. Aberrant activation of PKC-beta signaling may therefore contribute to oncogenic transcription in multiple cancer types. The link between H3T6 kinase activity and chromatin regulation provides a rationale for targeting this pathway in cancers with PKC-beta dysregulation.

Histone H3 phosphorylation is dynamically regulated during myoblast differentiation, and muscle-specific pyruvate kinase isoforms PKM1 and PKM2 regulate SWI/SNF proteins and H3 phosphorylation. This suggests that H3T6 kinase activity may play a role in muscle development and regeneration. Dysregulation of this process could contribute to muscle-related pathologies, although direct evidence for H3T6 in muscle disease is still emerging.

In vitro kinase assays using recombinant PKC-beta and histone H3 or H3 peptides can directly measure histone H3T6 kinase activity. These assays typically monitor incorporation of radiolabeled or fluorescent phosphate into the substrate. They are useful for confirming that a candidate enzyme carries the activity and for testing inhibitors.

Antibodies that specifically recognize histone H3 phosphorylated at threonine 6 enable detection of this mark in cell lysates by immunoblotting. Such antibodies can also be used in immunofluorescence to visualize the mark in situ. These reagents are essential for validating changes in H3T6 phosphorylation after genetic or pharmacological perturbations.

ChIP with anti-phospho-H3T6 antibodies can map the genomic distribution of this mark and correlate it with transcription. Combining ChIP with sequencing (ChIP-seq) allows genome-wide profiling of H3T6 phosphorylation. This approach helps determine whether the mark is enriched at specific promoters or enhancers.

CRISPR knockout, point mutation, and knock-in strategies can be used to dissect the function of PRKCB and histone H3 threonine 6. Library screening can identify genes that modulate sensitivity to PKC-beta inhibition or H3T6 phosphorylation. These methods provide causal evidence linking genotype to chromatin state.

Researchers studying histone H3T6 kinase activity-related genes often need to determine whether a candidate gene is causally involved in the modification, how the mark is regulated, and which downstream pathways it controls. EDITGENE provides a comprehensive suite of CRISPR-based services to build precisely engineered cell models for such investigations.

Histone H3T6 kinase activity (GO:0035403) is a specific molecular function that links kinase signaling to chromatin regulation through phosphorylation of histone H3 at threonine 6. The prototype enzyme PKC-beta controls H3K4 demethylation and is implicated in cancer, including Ewing sarcoma, while metabolic enzymes such as PKM isoforms influence H3 phosphorylation during differentiation. Understanding this activity requires integrating biochemical assays, chromatin profiling, and CRISPR-based genetic models. EDITGENE offers a full range of CRISPR services to help researchers dissect the mechanisms and disease relevance of histone H3T6 kinase activity.